Genetics of myeloid malignancies:: Pathogenetic and clinical implications

被引:260
作者
Fröhling, S
Scholl, C
Gilliland, DG
Levine, RL
机构
[1] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
关键词
D O I
10.1200/JCO.2005.05.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myeloid malignancies are clonal disorders that are characterized by acquired somatic mutation in hematopoietic progenitors. Recent advances in our understanding of the genetic basis of myeloid malignancies have provided important insights into the pathogenesis of acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) and have led to the development of novel therapeutic approaches. In this review, we describe our current state of understanding of the genetic basis of AML and MPD, with a specific focus on pathogenetic and therapeutic significance. Specific examples discussed include RAS mutations, KIT mutations, FLT3 mutations, and core binding factor rearrangements in AML, and JAK2 mutations in polycythemia vera, essential thrombocytosis, and chronic idiopathic myelofibrosis.
引用
收藏
页码:6285 / 6295
页数:11
相关论文
共 188 条
[51]   c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia [J].
Gari, M ;
Goodeve, A ;
Wilson, G ;
Winship, P ;
Langabeer, S ;
Linch, D ;
Vandenberghe, E ;
Peake, I ;
Reilly, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :894-900
[52]   CLONALITY IN MYELOPROLIFERATIVE DISORDERS - ANALYSIS BY MEANS OF THE POLYMERASE CHAIN-REACTION [J].
GILLILAND, DG ;
BLANCHARD, KL ;
LEVY, J ;
PERRIN, S ;
BUNN, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) :6848-6852
[53]   Treatment of hypereosinophilic syndrome with imatinib mesilate [J].
Gleich, GJ ;
Leiferman, KM ;
Pardanani, A ;
Tefferi, A ;
Butterfield, JH .
LANCET, 2002, 359 (9317) :1577-1578
[54]   FUSION OF PDGF RECEPTOR-BETA TO A NOVEL ETS-LIKE GENE, TEL, IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH T(512) CHROMOSOMAL TRANSLOCATION [J].
GOLUB, TR ;
BARKER, GF ;
LOVETT, M ;
GILLILAND, DG .
CELL, 1994, 77 (02) :307-316
[55]   The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia:: implications for diagnosis, classification, and management [J].
Gotlib, J ;
Cools, J ;
Malone, JM ;
Schrier, SL ;
Gilliland, DG ;
Coutré, SE .
BLOOD, 2004, 103 (08) :2879-2891
[56]  
Gotlib Jason, 2005, Curr Hematol Rep, V4, P77
[57]   ACTIVATION OF HA-RAS IN HUMAN CHRONIC GRANULOCYTIC AND CHRONIC MYELOMONOCYTIC LEUKEMIA [J].
GOW, J ;
HUGHES, D ;
FARR, C ;
HAMBLIN, T ;
OSCIER, D ;
BROWN, R ;
PADUA, RA .
LEUKEMIA RESEARCH, 1988, 12 (10) :805-810
[58]  
Gozzini A, 2003, CANCER RES, V63, P8955
[59]   p53-binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder [J].
Grand, FH ;
Burgstaller, S ;
Kühr, T ;
Baxter, EJ ;
Webersinke, G ;
Thaler, J ;
Chase, AJ ;
Cross, NCP .
CANCER RESEARCH, 2004, 64 (20) :7216-7219
[60]   The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].
Griffith, J ;
Black, J ;
Faerman, C ;
Swenson, L ;
Wynn, M ;
Lu, F ;
Lippke, J ;
Saxena, K .
MOLECULAR CELL, 2004, 13 (02) :169-178